BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bristol-Myers Squibb Co (BMY) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has positive financial performance and a promising pipeline, the stock faces insider selling, cautious congressional trading activity, and a bearish short-term trend. The lack of strong proprietary trading signals further supports a hold recommendation.
The technical indicators present a mixed picture. The MACD is positive but contracting, RSI is neutral at 62.531, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its pivot level (58.376) with resistance at 61.325 and support at 55.427. Short-term stock trends suggest a 60% chance of a decline (-1.77% in the next day, -5.69% in the next week, -9.36% in the next month).
Analysts have raised price targets and maintain mostly Buy ratings, citing a strong pipeline and growth potential.
Q4 2025 financials show significant YoY improvements in revenue (+1.30%), net income (+1409.72%), EPS (+1225.00%), and gross margin (+8.41%).
The company has a catalyst-rich pipeline with high-profile Phase 3 trials expected in 2026.
Insider selling has increased significantly (+15753.10% over the last month).
Congress members have shown a cautious stance with 4 sale transactions and no purchases in the last 90 days.
Short-term stock trends indicate a bearish outlook.
No proprietary trading signals (AI Stock Picker or SwingMax) are present to support a buy decision.
In Q4 2025, Bristol-Myers Squibb reported revenue of $12.5B (+1.30% YoY), net income of $1.087B (+1409.72% YoY), EPS of $0.53 (+1225.00% YoY), and a gross margin of 65.33% (+8.41% YoY). These results indicate strong financial growth and operational efficiency.
Most analysts maintain a positive outlook on BMY, with multiple firms raising price targets (e.g., Guggenheim to $72, BofA to $68, Truist to $65). Analysts highlight the company's strong pipeline and upcoming catalysts as key drivers for future growth. However, some firms, like Morgan Stanley, remain cautious with an Underweight rating and a lower price target of $40.
